Van Regenmortel Marc H V
CNRS, UMR7242 - Institut de Recherche de l'Ecole de Biotechnologie de Strasbourg (IREBS), Université de Strasbourg, Illkirch 67400, France Email:
AIMS Public Health. 2015 May 6;2(2):183-193. doi: 10.3934/publichealth.2015.2.183. eCollection 2015.
It is commonly assumed that neutralizing Mabs that bind to the HIV-1 Env glycoprotein are more specific reagents than anti-HIV-1 polyclonal antisera and that knowledge of the structure of these Mabs facilitates the rational design of effective HIV-1 vaccine immunogens. However, after more than ten years of unsuccessful experimentation using the structure-based reverse vaccinology approach, it is now evident that it is not possible to infer from the structure of neutralizing Mabs which HIV immunogens induced their formation nor which vaccine immunogens will elicit similar Abs in an immunized host. The use of Mabs for developing an HIV-1 vaccine was counterproductive because it overlooked the fact that the apparent specificity of a Mab very much depends on the selection procedure used to obtain it and also did not take into account that an antibody is never monospecific for a single epitope but is always polyspecific for many epitopes. When the rationale of the proponents of the unsuccessful rational design strategy is analyzed, it appears that investigators who claim they are designing a vaccine immunogen are only improving the binding reactivity of a single epitope-paratope pair and are not actually designing an immunogen able to generate protective antibodies. The task of a designer consists in imagining what type of immunogen is likely to elicit a protective immune response but in the absence of knowledge regarding which features of the immune system are responsible for producing a functional neutralizing activity in antibodies, it is not feasible to intentionally optimize a potential immunogen candidate in order to obtain the desired outcome. The only available option is actually to test possible solutions by trial-and-error experiments until the preset goal is perhaps attained. Rational design and empirical approaches in HIV vaccine research should thus not be opposed as alternative options since empirical testing is an integral part of a so-called design strategy.
人们通常认为,与HIV-1包膜糖蛋白结合的中和单克隆抗体(Mabs)是比抗HIV-1多克隆抗血清更具特异性的试剂,并且了解这些单克隆抗体的结构有助于合理设计有效的HIV-1疫苗免疫原。然而,在使用基于结构的反向疫苗学方法进行了十多年未成功的实验之后,现在很明显,无法从中和单克隆抗体的结构推断出哪些HIV免疫原诱导了它们的形成,也无法推断出哪些疫苗免疫原会在免疫宿主中引发类似的抗体。使用单克隆抗体来开发HIV-1疫苗适得其反,因为它忽略了这样一个事实,即单克隆抗体的表观特异性在很大程度上取决于用于获得它的选择程序,并且也没有考虑到抗体对单个表位从来不是单特异性的,而是对许多表位总是多特异性的。当分析不成功的合理设计策略支持者的基本原理时,似乎声称正在设计疫苗免疫原的研究人员只是在提高单个表位-互补位对的结合反应性,而实际上并没有设计出一种能够产生保护性抗体的免疫原。设计者的任务在于设想哪种类型的免疫原可能引发保护性免疫反应,但在缺乏关于免疫系统的哪些特征负责在抗体中产生功能性中和活性的知识的情况下,有意优化潜在的免疫原候选物以获得期望的结果是不可行的。唯一可行的选择实际上是通过反复试验来测试可能的解决方案,直到可能达到预设目标。因此,HIV疫苗研究中的合理设计和经验方法不应被视为相互对立的替代选项,因为经验测试是所谓设计策略的一个组成部分。